Latest Information Update: 28 Sep 2016
At a glance
- Originator 3SBio
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer
Most Recent Events
- 19 Sep 2016 Phase-I clinical trials in Colorectal cancer (Metastatic disease, Late-stage disease; Parenteral) before September 2016 (3SBio pipeline, September 2016)